Amarin Corp. ADR Stock
Amarin Corp. ADR Stock
Amarin Corporation plc (Symbol AMRN) is a biopharmaceutical company that is focused on the development and commercialization of therapeutics to improve cardiovascular health. The company's main product, Vascepa, is a prescription medication that has been approved by the US FDA for use as an adjunct to diet to reduce triglyceride levels in adults with severe hypertriglyceridemia. Vascepa has also shown to reduce the risk of cardiovascular events such as heart attack and stroke in patients with elevated cardiovascular risk. As a listed company, Amarin is publicly traded on the NASDAQ stock exchange and has a market capitalization of approximately $5 billion as of August 2021.
Pros and Cons of Amarin Corp. ADR in the next few years
Pros
Cons
Performance of Amarin Corp. ADR vs. its peers
Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
---|---|---|---|---|---|---|---|
Amarin Corp. ADR | 2.340% | 3.067% | -13.846% | -33.333% | 3.067% | -78.517% | -94.764% |
Genus plc | 2.020% | 4.124% | 1.508% | -32.935% | -18.745% | -64.561% | -28.672% |
Sage Therapeutics Inc. | -3.520% | 1.448% | -14.427% | -68.390% | -35.200% | -78.145% | - |
Ironwood Pharmaceuticals | -1.300% | 2.703% | 1.333% | -21.649% | -25.490% | -15.084% | - |
Comments
News
Amarin Plc (AMRN) Q1 2024 Earnings Call Transcript
Why Amarin Stock Was Rocketing Higher on Wednesday
Any one-product company that receives good news about that product will likely attract investors. That was the case Wednesday with Amarin (NASDAQ: AMRN), which received very encouraging news about